FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

Verger, Antoine; Yakushev, Igor; Albert, Nathalie L; van Berckel, Bart; Brendel, Matthias; Cecchin, Diego; Fernandez, Pablo Aguiar; Fraioli, Francesco; Guedj, Eric; Morbelli, Silvia; Tolboom, Nelleke; Traub-Weidinger, Tatjana; Van Weehaeghe, Donatienne; Barthel, Henryk

doi:https://doi.org/10.1007/s00259-023-06177-5

FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

DSpace/Manakin Repository

FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

Verger, Antoine; Yakushev, Igor; Albert, Nathalie L; van Berckel, Bart; Brendel, Matthias; Cecchin, Diego; Fernandez, Pablo Aguiar; Fraioli, Francesco; Guedj, Eric; Morbelli, Silvia; Tolboom, Nelleke; Traub-Weidinger, Tatjana; Van Weehaeghe, Donatienne; Barthel, Henryk

(2023) European Journal of Nuclear Medicine and Molecular Imaging, volume 50, issue 6, pp. 1553 - 1555

(Editorial)

Download/Full Text

Open Access version via Utrecht University Repository

Publisher version

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Alzheimer Disease/diagnostic imaging, Amyloid, Amyloid beta-Peptides, Humans, Neuroimaging, Positron-Emission Tomography, Editorial, Comment

DOI: https://doi.org/10.1007/s00259-023-06177-5

ISSN: 1619-7070

Publisher: Springer-Verlag

(Peer reviewed)